| Literature DB >> 19796706 |
Jose Antonio Chavez1, Scott A Summers.
Abstract
The accumulation of fat in tissues not suited for lipid storage has deleterious consequences on organ function, leading to cellular damage that underlies diabetes, heart disease, and hypertension. To combat these lipotoxic events, several therapeutics improve insulin sensitivity and/or ameliorate features of metabolic disease by limiting the inappropriate deposition of fat in peripheral tissues (i.e. thiazolidinediones, metformin, and statins). Recent advances in genomics and lipidomics have accelerated progress towards understanding the pathogenic events associated with the excessive production, underutilization, or inefficient storage of fat. Herein we review studies applying pharmacological or genetic strategies to manipulate the expression or activity of enzymes controlling lipid deposition, in order to gain a clearer understanding of the molecular mechanisms by which fatty acids contribute to metabolic disease. Copyright (c) 2009. Published by Elsevier B.V.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19796706 PMCID: PMC2868077 DOI: 10.1016/j.bbalip.2009.09.015
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002